About Dark Blue Therapeutics
Dark Blue Therapeutics is a company based in Oxford (United Kingdom) founded in 2020 was acquired by Amgen in January 2026. It operates as a B2B. Dark Blue Therapeutics offers products and services including Precision Oncology Drugs and Drug Pipeline. Dark Blue Therapeutics operates in a competitive market with competitors including Evotec, Crown Bioscience, Alloy Therapeutics, Domainex and NIH, among others.
- Headquarter Oxford, United Kingdom
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dark Blue Therapeutics Ltd
- Date of Incorporation 04 Jun, 2020
- Jurisdiction OXFORD, UNITED KINGDOM
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Dark Blue Therapeutics
Dark Blue Therapeutics offers a comprehensive portfolio of products and services, including Precision Oncology Drugs and Drug Pipeline.
Targets cancer dependencies for high-need patients through innovative development.
Delivers first-in-class drugs via academic insights and partnerships.
Funding Insights of Dark Blue Therapeutics
Detailed funding history for Dark Blue Therapeutics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Dark Blue Therapeutics
Dark Blue Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Amgen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of pharmaceutical products for treating multiple diseases
|
Locked | Locked | Locked |
Investor details for Dark Blue Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dark Blue Therapeutics
Investment portfolio details for Dark Blue Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Dark Blue Therapeutics
Detailed financials for Dark Blue Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dark Blue Therapeutics Comparisons
Peer comparison for Dark Blue Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dark Blue Therapeutics
Dark Blue Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evotec, Crown Bioscience, Alloy Therapeutics, Domainex and NIH, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery and development services are provided to biopharma sector.
|
|
| Locked | Locked | Locked |
Cancer and CVMD drugs are developed using PDX models.
|
|
| Locked | Locked | Locked |
Drug discovery services are provided for therapeutic development.
|
|
| Locked | Locked | Locked |
Drug discovery CRO company for epigenetic research and inflammatory diseases
|
|
| Locked | Locked | Locked |
Drug discovery services are provided to the biopharma sector.
|
|
| Locked | Locked | Locked |
Drug discovery and development research services are provided.
|
Detailed competitors of Dark Blue Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dark Blue Therapeutics
Complete news archive for Dark Blue Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dark Blue Therapeutics
Dark Blue Therapeutics was founded in 2020.
Dark Blue Therapeutics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Dark Blue Therapeutics focuses on reimagining cancer drug discovery by leveraging partnerships with world-leading academic experts. They exploit insights into cancer dependencies and driver mutations to create highly tuned precision medicines for patients with high unmet needs. The company operates from Oxford, United Kingdom, and maintains a pipeline of first-in-class drugs targeting various cancer mechanisms through innovative research and development.
Dark Blue Therapeutics's top competitors include Evotec, Crown Bioscience and NIH.
Dark Blue Therapeutics offers Precision Oncology Drugs and Drug Pipeline.
Dark Blue Therapeutics has 1 investor. Key investors include Amgen.